PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose

被引:82
作者
Panchapakesan, U
Sumual, S
Pollock, CA [1 ]
Chen, X
机构
[1] Royal N Shore Hosp, Dept Med, Kolling Inst Med Res, Renal Res Grp, St Leonards, NSW 2065, Australia
[2] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
关键词
thiazolidinediones; diabetic nephropathy; proximal tubular cells;
D O I
10.1152/ajprenal.00097.2005
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Peroxisome proliferator-activated receptor-gamma (PPAR gamma) are ligand- activated transcription factors that regulate cell growth, inflammation, lipid metabolism, and insulin sensitivity. We recently demonstrated that PPAR gamma agonists limit high glucose-induced inflammation in a model of proximal tubular cells (PTC; Panchapakesan U, Pollock CA, and Chen XM. Am J Physiol Renal Physiol 287: F528 - F534, 2004). However, the role of PPAR gamma in the excess extracellular matrix production is largely unknown. We evaluated the effect of 24- to 48-h 8 mu M L-805645 or 10 mu M pioglitazone on 25 mM D-glucose-induced markers of fibrosis in HK-2 cells. High D-glucose induced nuclear binding of activator protein-1 (AP-1) to 140.8 +/- 10.9% (P < 0.05), which was attenuated with L-805645 and pioglitazone to 82.3 +/- 14.4 (P < 0.01 vs. high D-glucose) and 99.3 +/- 12.2% (P < 0.05 vs. high D-glucose), respectively. High D-glucose increased total production of transforming growth factor (TGF)-beta(1) 139.6 +/- 6.5% (P < 0.05), which was reversed with L-805645 and pioglitazone to 68.73 +/- 5.7 (P < 0.01 vs. high D-glucose) and 112 +/- 13.6% (P < 0.05 vs. high D-glucose). L-805645 and pioglitazone reduced high D-glucose-induced fibronectin from 156.0 +/- 24.9 (P < 0.05) to 81.9 +/- 16.0 and 57.4 +/- 12.7%, respectively ( both P < 0.01 vs. high D-glucose). Collagen IV was not induced by high D-glucose. L-805645 and pioglitazone suppressed collagen IV to 68.0 +/- 14.5 (P < 0.05) and 46.5 +/- 11.6% (P < 0.01) vs. high D-glucose, respectively. High D-glucose increased the nuclear binding of NF-kappa B to 167 +/- 22.4% (P < 0.05), which was not modified with PPAR gamma agonists. In conclusion, PPAR gamma agonists exert antifibrotic effects in human PTC in high glucose by attenuating the increase in AP-1, TGF-beta(1), and the downstream production of the extracellular matrix protein fibronectin.
引用
收藏
页码:F1153 / F1158
页数:6
相关论文
共 39 条
[1]   ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1 [J].
Amann, B ;
Tinzmann, R ;
Angelkort, B .
DIABETES CARE, 2003, 26 (08) :2421-2425
[2]   Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation [J].
Asano, T ;
Wakisaka, M ;
Yoshinari, M ;
Iino, K ;
Sonoki, K ;
Iwase, M ;
Fujishima, M .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2000, 1497 (01) :148-154
[3]   The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].
Athyros, VG ;
Mikhailidis, DP ;
Papageorgiou, AA ;
Symeonidis, AN ;
Pehlivanidis, AN ;
Bouloukos, VI ;
Elisaf, M .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :728-734
[4]   Rosiglitazone reduces urinary albumin excretion in type II diabetes [J].
Bakris, G ;
Viberti, G ;
Weston, WM ;
Heise, M ;
Porter, LE ;
Freed, MI .
JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (01) :7-12
[5]  
Berger Joel, 2002, Diabetes Technol Ther, V4, P163, DOI 10.1089/15209150260007381
[6]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[7]   Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats [J].
Buckingham, RE ;
Al-Barazanji, KA ;
Toseland, CDN ;
Slaughter, M ;
Connor, SC ;
West, A ;
Bond, B ;
Turner, NC ;
Clapham, JC .
DIABETES, 1998, 47 (08) :1326-1334
[8]  
Chen J, 2003, J AM SOC NEPHROL, V14, p392A
[9]  
Collins R, 2003, LANCET, V361, P2005
[10]  
Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703